Cadila
-
{
- All
- News
- Videos
- Web Stories
-
Maharashtra FDA Acts Against Cadila Pharma; Bars Sale Of Two Sets Of Medicines Over Brand Confusion
FDA Commissioner Tukaram Mundhe said confusion caused by similar brand names, which could lead doctors, pharmacists or patients to administer the wrong drug, amounted to a serious public health concern.
-
Cadila Healthcare To Hive Off India Formulations Business
There will be no change in the shareholding pattern as business is transferred to a wholly owned subsidiary for cash consideration of Rs 69.3 crore, Cadila Healthcare said.
-
Cadila Healthcare To Hive Off India Formulations Business
There will be no change in the shareholding pattern as business is transferred to a wholly owned subsidiary for cash consideration of Rs 69.3 crore, Cadila Healthcare said.
-
Zydus Cadila Gets US Regulator's Nod For Drug, Shares Jump 2%
The company has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
-
Zydus Cadila Gets US Regulator's Nod To Sell Blood Pressure Drug
The group has now more than 150 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY2003-04, it added.
-
Zydus Cadila's Anti-Diabetic Drug Gets USFDA Marketing Nod
The company has received tentative approval to market sitagliptin and metformin hydrochloride.
-
Cadila Stock Jumps 9% On USFDA Approval For Hypertension Drug
The company will manufacture the drug at its facility in Moraiya, Ahmedabad.
-
Cadila Stock Jumps 9% On USFDA Approval For Hypertension Drug
The company will manufacture the drug at its facility in Moraiya, Ahmedabad.
-
Cadila Healthcare Gets EIR From USFDA For Moraiya Facility
Cadila Healthcare has received Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facility in Moraiya, indicating "closure of the inspection points" of initial review in 2014.
-
Zydus Cadila Gets USFDA Nod For Diabetes Treatment Drug
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Nateglinide tablets tablets USP, in the strengths of 60 mg and 120 mg, Zydus Cadila's group firm Cadila Healthcare said in a BSE filing.
-
Accumulate Cadila Healthcare; Buy Coal India: Pradip Hotchandani
Nifty is likely to go up to 8,655 as oscillators are strongly placed and investors should go long on Nifty with stop loss at 8,400, says Pradip Hotchandani, head of research at Prudent Broking Services.
-
Zydus To Sell Ulcerative Colitis Treatment Generic Drug In US Market
Drug firm Cadila Healthcare's US arm Zydus Pharmaceuticals (USA) Inc will start selling a generic version of Asacol HD, used for treatment of ulcerative colitis, in the American market from August 1, 2016.
-
Glenmark Pharma Seeks Foreign Partners on Biological Drugs
Glenmark Pharmaceuticals Ltd is in talks with foreign companies for a partnership on two of its biological drugs being tested for the treatment of chronic pain and autoimmune disorders, a senior executive said on Thursday.
-
Top 5 Pharma Companies Lose 19,000 Crore In Market Value. Here Is Why
Analysts say the fresh selloff in the pharmaceutical shares has been triggered after Sun Pharma's US-based subsidiary Taro Pharmaceuticals reported a weak set of earnings in the March quarter.
-
Cadila Healthcare Board Nod For Up To Fund Raising Up To Rs 18,500 Crore
Zydus Cadila group has global operations in four continents spread across the US, Europe, Latin America and South Africa and 25 other emerging markets.
-
Maharashtra FDA Acts Against Cadila Pharma; Bars Sale Of Two Sets Of Medicines Over Brand Confusion
FDA Commissioner Tukaram Mundhe said confusion caused by similar brand names, which could lead doctors, pharmacists or patients to administer the wrong drug, amounted to a serious public health concern.
-
Cadila Healthcare To Hive Off India Formulations Business
There will be no change in the shareholding pattern as business is transferred to a wholly owned subsidiary for cash consideration of Rs 69.3 crore, Cadila Healthcare said.
-
Cadila Healthcare To Hive Off India Formulations Business
There will be no change in the shareholding pattern as business is transferred to a wholly owned subsidiary for cash consideration of Rs 69.3 crore, Cadila Healthcare said.
-
Zydus Cadila Gets US Regulator's Nod For Drug, Shares Jump 2%
The company has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
-
Zydus Cadila Gets US Regulator's Nod To Sell Blood Pressure Drug
The group has now more than 150 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY2003-04, it added.
-
Zydus Cadila's Anti-Diabetic Drug Gets USFDA Marketing Nod
The company has received tentative approval to market sitagliptin and metformin hydrochloride.
-
Cadila Stock Jumps 9% On USFDA Approval For Hypertension Drug
The company will manufacture the drug at its facility in Moraiya, Ahmedabad.
-
Cadila Stock Jumps 9% On USFDA Approval For Hypertension Drug
The company will manufacture the drug at its facility in Moraiya, Ahmedabad.
-
Cadila Healthcare Gets EIR From USFDA For Moraiya Facility
Cadila Healthcare has received Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facility in Moraiya, indicating "closure of the inspection points" of initial review in 2014.
-
Zydus Cadila Gets USFDA Nod For Diabetes Treatment Drug
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Nateglinide tablets tablets USP, in the strengths of 60 mg and 120 mg, Zydus Cadila's group firm Cadila Healthcare said in a BSE filing.
-
Accumulate Cadila Healthcare; Buy Coal India: Pradip Hotchandani
Nifty is likely to go up to 8,655 as oscillators are strongly placed and investors should go long on Nifty with stop loss at 8,400, says Pradip Hotchandani, head of research at Prudent Broking Services.
-
Zydus To Sell Ulcerative Colitis Treatment Generic Drug In US Market
Drug firm Cadila Healthcare's US arm Zydus Pharmaceuticals (USA) Inc will start selling a generic version of Asacol HD, used for treatment of ulcerative colitis, in the American market from August 1, 2016.
-
Glenmark Pharma Seeks Foreign Partners on Biological Drugs
Glenmark Pharmaceuticals Ltd is in talks with foreign companies for a partnership on two of its biological drugs being tested for the treatment of chronic pain and autoimmune disorders, a senior executive said on Thursday.
-
Top 5 Pharma Companies Lose 19,000 Crore In Market Value. Here Is Why
Analysts say the fresh selloff in the pharmaceutical shares has been triggered after Sun Pharma's US-based subsidiary Taro Pharmaceuticals reported a weak set of earnings in the March quarter.
-
Cadila Healthcare Board Nod For Up To Fund Raising Up To Rs 18,500 Crore
Zydus Cadila group has global operations in four continents spread across the US, Europe, Latin America and South Africa and 25 other emerging markets.
